DelveInsight’s, “Psoriasis Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Psoriasis Research. Learn more about our innovative pipeline today! @ Psoriasis Pipeline Outlook

 

Key Takeaways from the Psoriasis Pipeline Report

• In October 2024:- Xantho Biotechnology Co., Ltd- This trial is a Phase IIa clinical trial. Around 65 subjects will be enrolled into this study to primarily assess the treatment efficacy of 5% GM-XANTHO in patients with psoriasis, as well as the safety and tolerability of 5% GM-XANTHO. Two third of the total subjects will be given the investigational product, 5% GM-XANTHO, and the other third will take placebo. The treatment period will last for 28 consecutive days, followed by a safety follow-up for 2 weeks. During the study, there will be 8 scheduled visits to the clinical center.
• In October 2024:- Bristol-Myers Squibb- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting. The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
• In October 2024:- Sanofi- This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It is designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details include a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (4 weeks ± 3 days). The total number of study visits will be 7.
• In October 2024;- AbbVie- The study will be broken up into 2 sub-studies by disease location, participants with moderate to severe genital psoriasis (Study G) and moderate to severe scalp psoriasis (Study S). In both sub-studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period.
• DelveInsight’s Psoriasis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Psoriasis treatment.
• The leading Psoriasis Companies such as Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
• Promising Psoriasis Therapies such as Hypericin, AX-158, Deucravacitinib, CMAB015, Secukinumab, Rimegepant, IBI112, BMS-986165, and others.

 

Stay informed about the cutting-edge advancements in Psoriasis treatments. Download for updates and be a part of the revolution in care @ Psoriasis Clinical Trials Assessment

 

Psoriasis Emerging Drugs Profile

• Topical roflumilast: Arcutis Biotherapeutics

Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). The therapy is in Phase III clinical development for the treatment of Plaque Psoriasis.

• GSK2982772: GlaxoSmithKline

GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. The molecule is in Phase I clinical development for the treatment of Psoriasis.

 

Learn more about Psoriasis Drugs opportunities in our groundbreaking Psoriasis Research and development projects @ Psoriasis Unmet Needs

 

Psoriasis Companies

Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.

 

Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

 

Psoriasis Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

 

Discover the latest advancements in Psoriasis treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Psoriasis Market Drivers and Barriers, and Future Perspectives

 

Scope of the Psoriasis Pipeline Report

• Coverage- Global
• Psoriasis Companies- Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
• Psoriasis Therapies- Hypericin, AX-158, Deucravacitinib, CMAB015, Secukinumab, Rimegepant, IBI112, BMS-986165, and others.
• Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Psoriasis Pipeline on our website @ Psoriasis Emerging Drugs and Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Psoriasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Psoriasis – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Psoriasis Collaboration Deals
9. Late Stage Products (Phase III)
10. CT-P43: Celltrion
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. EDP1815: Evelo Biosciences
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. AZD0284: AstraZeneca
17. Drug profiles in the detailed report…..
18. Early Stage Products (Preclinical)
19. AZD0284: AstraZeneca
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Psoriasis Key Companies
23. Psoriasis Key Products
24. Psoriasis- Unmet Needs
25. Psoriasis- Market Drivers and Barriers
26. Psoriasis- Future Perspectives and Conclusion
27. Psoriasis Analyst Views
28. Psoriasis Key Companies
29. Appendix

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/